TAK, US8740602052

Takeda reports VERDICT data before results for Takeda Pharmaceutical stock

Published on 10/21/2026 at 09:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

VERDICT cut ulcerative colitis complication risk 70 percent on October 19, 2026. Takeda Pharmaceutical stock has results scheduled for October 29, 2026.

Takeda's clinical and earnings calendar

VERDICT reported a hazard ratio of 0.33 on October 19, 2026.
First-quarter revenue reached JPY 1.22 trillion in fiscal 2026.
Takeda Pharmaceutical stock trades at EUR 17.80 at 9:32 a.m. CEST at Lang & Schwarz on October 21, 2026.
Takeda will release second-quarter results on October 29, 2026.

TAK, US8740602052, Illustration mit AI erstellt.

Takeda Pharmaceutical Company (ISIN US8740602052) reported VERDICT data showing that a stricter treatment target reduced ulcerative colitis complication risk by nearly 70 percent on October 19, 2026. MarketScreener reported a hazard ratio of 0.33 for the disease-clearance group against symptomatic remission.

VERDICT data change the picture

The Phase 4 study tested whether deeper remission targets could extend the time before ulcerative colitis complications. The primary comparison produced a hazard ratio of 0.33, with a 95 percent confidence interval of 0.17 to 0.67 and a P value of 0.0014, according to MarketScreener. The finding supports Takeda's effort to defend Entyvio in a competitive immunology market.

What does Q1 mean for earnings?

Takeda's first-quarter fiscal 2026 revenue was JPY 1,219.9 billion, while reported operating profit reached JPY 201.4 billion and net income was JPY 113.3 billion. Drillr said revenue fell 0.5 percent at constant exchange rates, even as reported revenue increased 10.2 percent because of currency effects. The contrast makes the October report important for judging whether product growth can offset generic competition.

Three events shape the year

Takeda's fiscal 2026 guidance, published on May 13, 2026, called for revenue of JPY 4,640.0 billion. The first-quarter figures followed on July 30, 2026 with revenue of JPY 1,219.9 billion. The October 19, 2026 VERDICT update added a hazard ratio of 0.33 to the clinical picture.

The next reporting date

Takeda will release fiscal 2026 second-quarter information on October 29, 2026, followed by an investor webcast on the same date, according to the company's investor information. The timing gives investors a defined checkpoint for Entyvio trends, plasma-derived therapies and the company's full-year outlook.

Stock price before the session

Takeda Pharmaceutical stock was trading in pre-market activity at EUR 17.80 at Lang & Schwarz on October 21, 2026 at 9:32 a.m. CEST. The quotation provides the market's euro reference ahead of the company's second-quarter update, while the clinical data and first-quarter figures supply the operating context.

The further course of trading is shown by the continuously updated real-time quote of Takeda Pharmaceutical stock.